Warfarin pharmacogenomics

P and T

Volumn 34, Issue 8, 2009, Pages 422-427

  Li, Jiayi ^a   Wang, Shan ^b   Barone, Joseph ^c   Malone, Brian ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 HYDROXYWARFARIN; 6 HYDROXYWARFARIN; 7 HYDROXYWARFARIN; 8 HYDROXYWARFARIN; ATOMOXETINE; AZATHIOPRINE; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; IRINOTECAN; MENADIONE EPOXIDE; MERCAPTOPURINE; PROTHROMBIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; DEEP VEIN THROMBOSIS; DRUG CLEARANCE; DRUG METABOLISM; ENANTIOMER; ENZYME POLYMORPHISM; GENE FREQUENCY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; PHARMACOGENOMICS; RACEMIC MIXTURE; REGRESSION ANALYSIS; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 70350144265     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Shurin SB, Nabel EG. Pharmacogenomics: Ready for prime time? N Engl J Med 2008;358(10):1061-1063.
2. Kamali F, King BP, Frearson R, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004;75:204-212. (Pubitemid 38314870)
3. Schwarz UI, Stein CM. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants. Clin Pharmacol Ther 2006;80:7-12.
4. Zhu Y, Shennan M, Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP 2C9 genotypes. Clin Chem 2007;53(7):1199-1205. (Pubitemid 47020974)
5. Rettie AE, Tai GY. The pharmacogenomics of warfarin: Closing in on personalized medicine. Mol Interv 2006;6(4):223-226.
6. Hill CE, Duncan A. Overview of pharmacogenetics in anticoagulation therapy. Clin Lab Med 2008;28(4):513-524.
7. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: Regulatory, scientific, and clinical issues. J Thromb Thrombol 2008;25:45-51.
8. Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy 2008;28(9):1084-1097.
9. Khan T, Kamali F, Daly A, et al. Warfarin sensitivity: Be aware of genetic influence. Age Aging 2003;32:226-227. (Pubitemid 36372433)
10. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008;358:999-1008. (Pubitemid 351347099)
11. Li T, Lange LA, Li X, et al. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 2006;43:740-744. (Pubitemid 44483917)
12. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287(13):1690-1698.
13. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 2005;106(7):2329-2333.
14. Lindh JD, Lundgren S, Holm L, et al. Pharmacogenetics and genomics: Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 2005;78:540-550.
15. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007;116(22):2563-2570.
16. Singh AJ, Emery JO. Pharmacogenomics: The potential of genetically guided prescribing. Aust Fam Physician 2007;36(10):820-824.
17. Bussey HI, Wittkowsky AK, Hylek EM, et al. Genetic testing for warfarin dosing? Not yet ready for prime time. Pharmacotherapy 2008;28(2):141-143.
18. Eckman MH, Rosand J, Greenberg SM, et al. Cost effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009;150:73-83.